Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Escalating Dose, 6 Month Phase III Safety Study Of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism

NCT01534208 is registered in ClinicalTrials.gov with Repros Therapeutics Inc. as lead sponsor.

NCT NCT01534208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01534208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Escalating Dose, 6 Month Phase III Safety Study Of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism
Lead sponsor
Repros Therapeutics Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2012
Completion date
October 31, 2013
Enrollment
499 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

secondary hypogonadism